Tuesday, June 26, 2007 :: Imaging Diagnostic Systems Releases CT Laser Mammography
Imaging Diagnostic Systems Releases CT Laser Mammography
Breast Cancer Clinical Study Results

CTLM® Improves Clinical Performance

Fort Lauderdale, Florida, June 26, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced the release and publication of select results highlighting the advantages of using CT laser breast imaging as an adjunct to conventional mammography to improve detection of occult cancers in dense breasts.

“These CTLM results are being released as a response to the growing number of requests for performance statistics received from distributors and prospective customers worldwide. The results were obtained from our initial PMA-designed clinical study,” commented Tim Hansen, IMDS Chief Executive Officer.

“The findings are quite positive,” stated Eric Milne, MD, IMDS Director of Clinical Research. “The study, from four sites in North America, involving 705 breasts of 515 patients, biopsied in 451 cases, was scientifically rigorous. It demonstrated that, in a dense breast population, the adjunctive use of CTLM, classifying DCIS as malignant, increased sensitivity from 50.0 to 58.3% over mammography alone and improved specificity from 75.5 to 86.8%. When DCIS is classified as pre-malignant, the figures changed slightly, increasing sensitivity from 43.8% to 56.2% over mammography alone and improving specificity from 73.6% to 84.4%. The difference between the two sets of results reflects, we believe, that the pathologically ‘benign’ form of DCIS shows angiogenesis in only 30% of cases, whereas comedocarcinoma shows angiogenesis in 75%, an observation that that might prove useful for stratifying DCIS for treatment purposes. One of the more remarkable results of using CTLM as an adjunct was that specificity also improved along with sensitivity, reducing the negative biopsy rate.”

Hansen added, “The combination of these results, plus the publication of CTLM research results in the peer-reviewed journal Investigative Radiology and routine clinical use results in the Egyptian Journal of Radiology, should provide confidence in the clinical merits of our technology. We have also completed over 9,000 CTLM breast studies in various global sites. We believe that releasing these results will reinforce the clinical value of our CTLM studies until the outcome of our current US PMA study is disclosed.”

The results, presented in the tables below, were published in Vol. 16, Issue 3/07, Mammo-Update 10, of European Hospital.







DCIS classified as malignant:
Sensitivity Specificity NPV PPV
Mammography alone 50.0% 75.5% 90.9% 23.5%
Mammography + CTLM 58.3% 86.8% 93.2% 40.0%
P-value 0.56 0.01
DCIS classified as ‘pre-malignant’:
Sensitivity Specificity NPV PPV
Mammography alone 43.8% 73.6% 93.2% 13.7%
Mammography + CTLM 56.2% 84.4% 95.3% 25.7%
P-value 0.41 0.02


About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) application for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com

Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com

Thursday, June 7, 2007 :: Imaging Diagnostic Systems Laser Breast Imaging Technology Presented at China’s Leading Breast Disease Conference
Imaging Diagnostic Systems Laser Breast Imaging Technology Presented at China’s Leading Breast Disease Conference

Fort Lauderdale, Florida, June 7, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, participated in the 2nd National Imaging Diagnostic Conference on Breast Disease in Qingdao, China, May 25-27, 2007. The Conference is considered the most important venue on breast disease in China.

Dr. Run-Xian Bao, Chairman of the Tianjin Tumor Hospital Radiology Department, the largest breast disease center in China, gave an introductory presentation on the new CT Laser Mammography (CTLM®) clinical technology. The CTLM presentation was published in the collective articles of the conference.

“Approximately 180 doctors attended this conference, the leaders in the study of breast cancer. Many were very interested in how CT Laser Mammography systems could help improve cancer detection methods or be used to track a patient’s progress through neoadjuvant therapy,” stated Mr. Jing Jie Zhuang, Managing Director, IDSI Beijing.

“We are very pleased with the growing interest we are seeing as we build our clinical presence in China. Having a direct office in Beijing has greatly helped IMDS establish close relations with leading Chinese breast specialists for both research and commercial opportunities. Beijing Friendship Hospital has been a key CTLM clinical collaborator,” Zhuang continued.

IMDS has received approval for the CTLM system from the State Food and Drug Administration of the People’s Republic of China (SFDA), the Chinese equivalent of the US Food and Drug Administration. As announced previously, according to the Beijing Municipal Commission of Development & Reform and the Beijing Municipal Health Bureau, CTLM procedures may be priced up to RMB300 ($38 at the current exchange rate) per breast as listed on the “Interim Procedures for Beijing Medical Service Price” schedule.



About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) application for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com

Media Contact:
Elizabeth Williams
(954) 581-9800
williams@imds.com

Wednesday, April 18, 2007 :: Imaging Diagnostic Systems’ Director of Clinical Research Cautions Against Excess Radiation Dose to Breasts
Imaging Diagnostic Systems’ Director of Clinical Research Cautions Against Excess Radiation Dose to Breasts

Contributes Chapter to Upcoming Lung and Breast Cancer Imaging Publication

Fort Lauderdale, Florida, April 18, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced that Professor Eric Milne, M.D., IDSI Director of Clinical Research, has contributed to a comprehensive new book, “Cancer Imaging: Lung and Breast Carcinomas,” edited by Professor M.A. Hayat.

Professor Milne’s chapter, “Breast Dose in Thoracic Computed Tomography,” examines the risks of inducing breast cancer as a result of the ionizing radiation received during CT exams of the thorax and upper abdomen. Citing results stemming from his original 1992 study, which demonstrated that large doses of ionizing radiation, equivalent to the dose from 15 to 60 mammograms, are absorbed by the female breast as a result of each chest CT exam, Milne suggests that referring physicians should carefully weigh the clinical necessity for thoracic scans in female and pediatric patients and cautions against the use of CT scans as a screening procedure for lung cancer, coronary artery calcification, or pediatric lung disease.

“The number of CT scans performed per year, for every 1,000 persons, has increased enormously in the USA over the last five years,” Milne explains. “We now hold the world record at 172.5 scans for every group of 1,000 people. A conservative estimate of the carcinogenic effects of this massive irradiation would indicate an increase of 16,000 breast cancers.”

Commented Tim Hansen, IDSI President and CEO: “We believe that imaging the angiogenesis process using lasers not only presents new information to the diagnostician, but also avoids adding to the patient’s cumulative carcinogenic radiation dose. As Dr. Milne notes, physicians should be aware of the dose consequences and examine alternatives that are available.”

The book, which will be published by Elsevier, is currently in press.

About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our corporate website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, April 17, 2007 :: Imaging Diagnostic Systems’ CT Laser Mammography Attracts Media Attention at European Congress of Radiology 2007
Imaging Diagnostic Systems’ CT Laser Mammography Attracts Media Attention at European Congress of Radiology 2007

Study Results Compared CTLM to MR for Detecting Remaining Angiogenesis after Neoadjuvant Therapy

Fort Lauderdale, Florida, April 17, 2007—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, attracted media attention at the European Congress of Radiology (ECR) 2007, March 9-13 in Vienna, Austria, with the results of a comparison study of CT Laser Mammography (CTLM) and MR. Featured in a poster at the company’s exhibit, the results are from a work-in-progress study conducted by physicians at Catholic University in Rome, Italy. The results compare CTLM to MR for detecting remaining angiogenesis after neoadjuvant therapy and suggest that CTLM may be more sensitive than MR for treatment monitoring.

The study results and CTLM technology were featured in a March 21 article on medicalphysicsweb.org, a community website of the Institute of Physics in the United Kingdom. The article is featured on the medicalphysicsweb website at http://medicalphysicsweb.org/cws/article/industry/27370. A quick registration with the site is required to view the article.

Deborah O’Brien, IDSI Senior Vice President, commented: “At ECR 2007, we were able to generate commercial and clinical exposure in one of our most important markets. We introduced CTLM and the principles behind our technology to European physicians, members of the media, and other radiologic professionals who were unfamiliar with the clinical and scientific fundamentals. At the same time, we informed attendees who are already familiar with CTLM of our progress and developments. The meeting allowed us to build on the momentum in Europe created by our clients and luminary partners and establish new relationships within the global radiology community.”

One of the leading international events in radiology, ECR 2007 attracted over 17,000 attendees from 94 countries.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our corporate website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com